MetLife Investment Management
NKTR icon

MetLife Investment Management’s Nektar Therapeutics NKTR Stock Holding History

MetLife Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.4M Buy
+20,087
New +$1.47M 0.01% 1352
2025
Q2 		– Sell
-2,033
Closed -$20.7K – 2895
2025
Q1 		$20.7K Sell
2,033
-5,067
-71% -$66.2K ﹤0.01% 2747
2024
Q4 		$99.1K Hold
7,100
– – ﹤0.01% 2628
2024
Q3 		$138K Buy
7,100
+4,000
+129% +$76.2K ﹤0.01% 2473
2024
Q2 		$57.7K Buy
+3,100
New +$65.3K ﹤0.01% 2737
2023
Q2 		– Sell
-4,057
Closed -$42.8K – 2971
2023
Q1 		$42.8K Sell
4,057
-2,279
-36% -$68.9K ﹤0.01% 2728
2022
Q4 		$215K Hold
6,336
– – ﹤0.01% 2206
2022
Q3 		$304K Hold
6,336
– – ﹤0.01% 2011
2022
Q2 		$361K Buy
6,336
+6,097
+2,551% +$385K ﹤0.01% 1885
2022
Q1 		$19.4K Buy
+239
New +$35.4K ﹤0.01% 2710
2021
Q4 		– Sell
-5,887
Closed -$1.59M – 2534
2021
Q3 		$1.59M Sell
5,887
-186
-3% -$44.7K 0.01% 946
2021
Q2 		$1.56M Sell
6,073
-201
-3% -$55.6K 0.01% 964
2021
Q1 		$1.88M Sell
6,274
-271
-4% -$84.3K 0.02% 891
2020
Q4 		$1.67M Sell
6,545
-283
-4% -$73.1K 0.02% 914
2020
Q3 		$1.7M Sell
6,828
-219
-3% -$68.9K 0.02% 788
2020
Q2 		$2.45M Buy
7,047
+315
+5% +$98.3K 0.03% 632
2020
Q1 		$1.8M Hold
6,732
– – 0.02% 653
2019
Q4 		$2.18M Buy
6,732
+3,552
+112% +$1.03M 0.02% 775
2019
Q3 		$869K Sell
3,180
-23
-0.7% -$8.44K 0.01% 1139
2019
Q2 		$1.71M Sell
3,203
-6,690
-68% -$3.35M 0.02% 880
2019
Q1 		$4.99M Buy
9,893
+6,595
+200% +$3.91M 0.01% 868
2018
Q4 		$1.63M Sell
3,298
-45
-1% -$27.2K 0.02% 841
2018
Q3 		$3.06M Buy
3,343
+181
+6% +$154K 0.03% 657
2018
Q2 		$2.32M Sell
3,162
-4,530
-59% -$5.22M 0.03% 742
2018
Q1 		$12.3M Buy
7,692
+3,228
+72% +$4.16M 0.14% 132
2017
Q4 		$4M Buy
+4,464
New +$2.64M 0.05% 469

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MetLife Investment Management's NKTR Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 20,087 shares worth $1.4M. The stake represents 0.01% of the portfolio and ranks #1352 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in NKTR as recently as Q1 2025.

MetLife Investment Management first reported a position in NKTR in Q4 2017 and has held it in 26 quarters since. The position peaked at $12.3M in Q1 2018. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • MetLife Investment Management held 20,087 shares of Nektar Therapeutics worth $1.4M as of Q2 2026.
  • Nektar Therapeutics was a new MetLife Investment Management position in Q2 2026.
  • Nektar Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1352 holding.
  • MetLife Investment Management first reported a position in Nektar Therapeutics in Q4 2017 and has held it in 26 quarters since.
  • MetLife Investment Management's Nektar Therapeutics position peaked at $12.3M in Q1 2018.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.